Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis
AUTOR(ES)
Façanha, Mônica C., Gondim, Argina M.B., Pinheiro, Valéria G.F., Barroso, Elizabeth C., Peloquin, Charles A., Guerrant, Richard L., Lima, Aldo A.M.
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2009-06
RESUMO
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The intestinal paracellular transport of lactulose was significantly (p = 0.019) reduced in cases compared to controls. The transcellular transport of mannitol and the lactulose:mannitol ratio were not significantly (p = 0.0698) reduced in cases compared to controls. Low serum concentrations of rifampin, isoniazid and pyrazinamide were observed in 81% (48/59), 92% (54/59) and 28% (12/59), respectively, in all individuals. The results demonstrated a marked decrease on intestinal paracellular transport in patients with active pulmonary tuberculosis and reduced serum concentrations of rifampin and isoniazid in both groups.
Documentos Relacionados
- Serum pyrazinamide concentrations in patients with pulmonary tuberculosis
- Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
- Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
- Barreira funcional intestinal, absorÃÃo e biodisponibilidade de Rifampicina, Isoniazida e Pirazinamida em pacientes com tuberculose pulmonar ativa
- Chemotherapeutic Potential of Orally Administered Poly(Lactide-Co-Glycolide) Microparticles Containing Isoniazid, Rifampin, and Pyrazinamide against Experimental Tuberculosis